Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Chokri Ben Lamine: Platelet Subpopulations and Targeted Therapies Across Evidence Levels
Apr 14, 2026, 09:01

Chokri Ben Lamine: Platelet Subpopulations and Targeted Therapies Across Evidence Levels

Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:

“Study Stage / Evidence Level – Platelet Subpopulation – Targeted Therapies

Reversible P2Y12 inhibitors (ticagrelor / cangrelor)

  • Stage: Phase III (established clinical practice)
  • PLATO trial – robust RCT evidence – guideline standard in ACS
  • Highest level evidence (Class I recommendation in cardiology guidelines)

GPVI inhibitors (glenzocimab, revacept)

  • Stage: Phase II clinical trials
  • PCI studies – good safety (decreased bleeding)
  • Efficacy signal modest – no reduction in MI yet
  • Promising but NOT standard of care

PI3K inhibition (LY294002)

  • Stage: Preclinical / experimental
  • Mechanistic targeting only
  • No clinical application currently

COX-2 targeting / aspirin adjustment

  • Stage: Mixed clinical data (small trials / observational)
  • No consistent benefit – not guideline recommended
  • Conceptual explanation for aspirin resistance

Platelet–immune axis (VEGF / PDGF / αIIbβ3 in cancer)

  • Stage: Early clinical / exploratory (e.g., APOLLO study)
  • Signal for improved outcomes with ICI combinations
  • Hypothesis-generating – not standard oncology practice

S100A8/A9 inhibitors (ABR-215757)

  • Stage: Preclinical models
  • Demonstrated decreased RP-driven thrombosis
  • No human outcome trials yet

SGLT2 inhibitors (indirect platelet modulation)

  • Stage: Phase III cardiovascular outcome trials (indirect evidence)
  • Proven decreased CV events – platelet benefit inferred
  • Not platelet-specific indication but clinically relevant

Summary hierarchy (very high yield)

Phase III / Standard: Ticagrelor / Cangrelor

Phase II / Emerging: GPVI inhibitors

Preclinical / Experimental:

  • PI3K inhibitors
  • S100A8/A9 inhibitors

Hypothesis / Mixed evidence:

  • COX-2 targeting
  • Platelet–immune modulation

Clinical pearl

  • Only P2Y12 reversible inhibitors currently translate platelet subpopulation biology into routine practice.
  • Everything else is precision medicine pipeline (future hematology/cardiology integration).”

Other posts featuring Chokri Ben Lamine on Hemostasis Today.

Aspirin bleeding disorders Cangrelor Chokri Ben Lamine glenzocimab GPVI inhibitors Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine P2Y12 Inhibitors Platelet revacept ticagrelor
NewsFeed